Zimmer Biomet (NYSE: ZBH) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares Zimmer Biomet and Antares Pharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zimmer Biomet $7.68 billion 3.02 $305.90 million $3.18 36.03
Antares Pharma $52.22 million 5.82 -$24.33 million ($0.11) -17.64

Zimmer Biomet has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zimmer Biomet and Antares Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet 1 6 14 1 2.68
Antares Pharma 0 0 3 1 3.25

Zimmer Biomet currently has a consensus price target of $135.40, suggesting a potential upside of 18.18%. Antares Pharma has a consensus price target of $3.95, suggesting a potential upside of 103.61%. Given Antares Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Antares Pharma is more favorable than Zimmer Biomet.

Profitability

This table compares Zimmer Biomet and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zimmer Biomet 8.36% 16.29% 6.17%
Antares Pharma -32.06% -43.05% -24.14%

Dividends

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.8%. Antares Pharma does not pay a dividend. Zimmer Biomet pays out 30.2% of its earnings in the form of a dividend.

Risk and Volatility

Zimmer Biomet has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Institutional and Insider Ownership

86.2% of Zimmer Biomet shares are held by institutional investors. Comparatively, 34.7% of Antares Pharma shares are held by institutional investors. 1.1% of Zimmer Biomet shares are held by company insiders. Comparatively, 11.6% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zimmer Biomet beats Antares Pharma on 10 of the 15 factors compared between the two stocks.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company’s product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

About Antares Pharma

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.